Announces strategic clinical trial plans for tecarfarin in patients with End-Stage Kidney Disease (ESKD) transitioning to dialysis Tecarfarin can potentially address critical treatment gaps in patients with ESKD Pivotal step forward in pursuit of ESKD + Atrial Fibrillation (AFib) registration trial PONTE VEDRA, Fla. / Aug 11, 2025 / Business Wire / Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company... Read More